Latest Wearables News

dorsaVi has completed the design of its first integrated RRAM-CMOS validation chip, featuring self-checking write-and-verify, compute-in-memory capabilities, and scalable integration on commercial CMOS wafers. The milestone sets the stage for fabrication and commercial engagement in high-value edge AI markets.

Nanoveu’s EMASS technology achieves real-time, always-on keyword spotting using bone-conduction vibration on the ECS-DoT edge AI chip at under 1 milliwatt power, eliminating the need for microphones and overcoming key challenges in wearable voice interfaces.

InteliCare (ASX:ICR) is hitting a commercial inflection point, backed by a landmark $8.8 million contract with mecwacare and a growing pipeline across aged care sectors. Its AI-powered platform promises measurable improvements in care outcomes and operational efficiency.

Simble Solutions is on the cusp of revealing initial results from its NanoSensor technology development, targeting major markets including Industrial IoT, defence sensing, and wearable medical devices.

dorsaVi has secured exclusive rights to two key robotics patents from NTU Singapore, filling critical gaps in safety control and data acquisition to expand into collaborative robotics and exoskeleton markets.

Alterity Therapeutics has clinched FDA agreement on the pivotal Phase 3 trial design for ATH434, targeting Multiple System Atrophy, with the trial set to begin by the end of 2026.

Nanoveu Limited has completed tape-out of its next-generation 16nm ECS-DoT AI chip, progressing its ultra-low-power edge AI commercialisation, while bolstering its drone systems capabilities through the Spinoff Robotics acquisition.

dorsaVi reveals that integrating RRAM and neuromorphic computing into its sensor platform could halve sensor count and more than double battery life in lower-limb exoskeletons, positioning the company as a key intelligence partner in a $1.79 billion market.

Control Bionics advances its neural-signal technology across assistive communication, sports, and medical sectors, securing key US reimbursement and distribution agreements while broadening its international footprint.

Simble Solutions has launched a strategic collaboration with Macquarie University to accelerate development of its exclusive zinc oxide nanosensor technology, targeting e-skin applications and integration into its IoT platforms.

Bio-Gene Technology has raised A$3.21 million to complete critical safety studies for its novel insecticide Flavocide and ramp up production of its natural insecticide Qcide, advancing its path to commercialisation in multiple global markets.

Catapult Sports Ltd (ASX:CAT) delivered a 20.8% revenue increase to US$140.7 million in FY26, driven by strong SaaS growth and strategic acquisitions, while management EBITDA surged 67%. Despite this, the company reported a net loss of US$24 million, impacted by non-cash expenses and acquisition costs.